Piper Jaffray Reiterates Overweight on Rovi Corp. (ROVI) Following AT&T/DTV License Agreement

Rovi Corp. (ROVI) Breaks Out to Highs on Sony Renewal

Rovi Corp. (NASDAQ: ROVI) broke out to the highs of the day following earlier news that the company renewed its worldwide license agreement with Sony.

Last week, shares of Rovi surged on the extension of the AT&T contract.

Comcast and... More

Rovi Corp. (ROVI) Pushes to Highs

Rovi Corp. (NASDAQ: ROVI) pushes near the highs of the session after this morning's upgrade, which follows yesterday's 29% move on the extension of the AT&T contract. Analysts say that Comcast and Echostar are likely to follow suit. Shares last traded up 7.8% to $15.80.

Rovi's (ROVI) AT&T Renewal Clears the Way to a $30+ Share Price - B. Riley

B. Riley analyst, Eric Wold, thinks that Rovi's (NASDAQ: ROVI) AT&T renewal signals that Comcast (NASDAQ: CMCSA) and Echostar (NASDAQ: DISH) are likely to follow suit. Although he isn't making any changes to his model today, he notes that his model has conservatism built into it (since the renewed contract terms were unknown) and implies that positive EPS revisions are possible if not likely.

Following the news that Rovi Corporation... More

Cowen Upgrades Rovi Corp. (ROVI) to Outperform

Cowen upgraded Rovi Corp. (NASDAQ: ROVI) from Market Perform to Outperform with a price target of $25.00 (from $11.00).

Analyst Robert Stone commented, "We believe the seven-year IP license with AT&T (announced 12/23) greatly reduces uncertainty about remaining renewals. The inflation-adjusted annual fee... More

Market Wrap: Durable Goods Orders Outpaced in Nov.; Crude Rises on Surpise Inventory Drop; KaloBios Gets Delisting Notice

Market wrap for December 23rd

End of the Day: S&P 500 up 25.3 to 2,064.29; Dow Jones up 185.3 to 17,602.61; Nasdaq up 44.8 to 5,045.93

Market Brief: Markets rose on the back of surging commodities gains, as the EIA reported a surprise drop in crude stockpiles last week.

Existing home sales, like pending home sales earlier in the week, came in lighter than expected for November.

Durable goods orders were flat last month, outpacing consensus estimates.

Pep Boys deemed Icahn's revised offer as "superior proposal," while... More

Unusual 11 Mid-Day Movers 12/23: (ADMS) (MEMP) (SXE) Higher; (NWBO) (GBSN) (STEM) Lower

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) 51.8% HIGHER; announced that its Phase 3 EASE LID clinical trial evaluating the companys investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinsons disease met its primary endpoint. Results from this randomized, placebo-controlled study showed a statistically significant reduction (p = 0.0009) in LID at 12 weeks for patients who received ADS-5102 versus placebo as assessed by the Unified Dyskinesia Rating Scale (UDysRS). This represents a 23 percent reduction in LID for ADS-5102-treated patients compared to placebo. The reduction... More

Pre-Open Stock Movers 12/23: (ADMS) (ROVI) (CELG) Higher; (GBSN) (BBBY) (MU) Lower (more...)

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) 34% HIGHER; announced that its Phase 3 EASE LID clinical trial evaluating the companys investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinsons disease met its primary endpoint. Results... More

Rovi Corp. (ROVI) Extends AT&T Contract by 7-Years

Rovi Corporation (NASDAQ: ROVI) today announced that Rovi has renewed its patent license agreement with AT&T, the worlds leading provider of premium TV entertainment. The comprehensive seven-year agreement provides AT&T worldwide access to Rovis best-in-class entertainment discovery patent portfolio. The... More